Taysha Gene Net Worth
Taysha Gene Net Worth Breakdown | TSHA |
Taysha Gene Net Worth Analysis
Taysha Gene's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Taysha Gene's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Taysha Gene's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Taysha Gene's net worth analysis. One common approach is to calculate Taysha Gene's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Taysha Gene's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Taysha Gene's net worth. This approach calculates the present value of Taysha Gene's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Taysha Gene's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Taysha Gene's net worth. This involves comparing Taysha Gene's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Taysha Gene's net worth relative to its peers.
Enterprise Value |
|
To determine if Taysha Gene is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Taysha Gene's net worth research are outlined below:
| Taysha Gene had very high historical volatility over the last 90 days | |
| Taysha Gene may become a speculative penny stock | |
| Taysha Gene has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 15.45 M. Net Loss for the year was (111.57 M) with profit before overhead, payroll, taxes, and interest of 2.5 M. | |
| Taysha Gene Therapies currently holds about 66.24 M in cash with (73.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.61. | |
| Taysha Gene has a frail financial position based on the latest SEC disclosures | |
| Over 77.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Needham Company LLC Reiterates Buy Rating for Taysha Gene Therapies |
Taysha Gene uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Taysha Gene Therapies. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Taysha Gene's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Taysha Gene's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Taysha Gene is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Taysha Gene Therapies backward and forwards among themselves. Taysha Gene's institutional investor refers to the entity that pools money to purchase Taysha Gene's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tybourne Capital Management (hk) Ltd | 2024-09-30 | 3.7 M | Geode Capital Management, Llc | 2024-09-30 | 3.6 M | State Street Corp | 2024-09-30 | 3.5 M | Polar Capital Holdings Plc | 2024-09-30 | 3 M | Jpmorgan Chase & Co | 2024-09-30 | 3 M | Citadel Advisors Llc | 2024-09-30 | 2.9 M | Deutsche Bank Ag | 2024-09-30 | 2.6 M | Ghost Tree Capital, Llc | 2024-09-30 | 2.1 M | Longwood Capital Partners Llc | 2024-09-30 | 2.1 M | Fmr Inc | 2024-09-30 | 18.7 M | Venbio Select Advisor Llc | 2024-09-30 | 18.6 M |
Follow Taysha Gene's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 395.54 M.Market Cap |
|
Project Taysha Gene's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.58) | (0.61) | |
| Return On Capital Employed | (0.61) | (0.58) | |
| Return On Assets | (0.58) | (0.61) | |
| Return On Equity | (1.71) | (1.80) |
When accessing Taysha Gene's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Taysha Gene's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Taysha Gene's profitability and make more informed investment decisions.
Please note, the presentation of Taysha Gene's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Taysha Gene's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Taysha Gene's management manipulating its earnings.
Evaluate Taysha Gene's management efficiency
Taysha Gene Therapies has return on total asset (ROA) of (0.2742) % which means that it has lost $0.2742 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1477) %, meaning that it created substantial loss on money invested by shareholders. Taysha Gene's management efficiency ratios could be used to measure how well Taysha Gene manages its routine affairs as well as how well it operates its assets and liabilities. As of January 10, 2025, Return On Tangible Assets is expected to decline to -0.61. The current year's Return On Capital Employed is expected to grow to -0.58. At present, Taysha Gene's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 3.3 M, whereas Total Assets are forecasted to decline to about 169.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.74 | 0.71 | |
| Tangible Book Value Per Share | 0.74 | 0.71 | |
| Enterprise Value Over EBITDA | (1.05) | (1.10) | |
| Price Book Value Ratio | 2.47 | 2.59 | |
| Enterprise Value Multiple | (1.05) | (1.10) | |
| Price Fair Value | 2.47 | 2.59 | |
| Enterprise Value | 141.1 M | 134.1 M |
Examining the leadership quality of Taysha Gene Therapies offers valuable insights into its operational efficiency and financial health. This analysis assists investors in making informed decisions regarding the stock.
Enterprise Value Revenue 29.263 | Revenue | Quarterly Revenue Growth (0.62) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Taysha Gene insiders, such as employees or executives, is commonly permitted as long as it does not rely on Taysha Gene's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Taysha Gene insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Taysha Gene time-series forecasting models is one of many Taysha Gene's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Taysha Gene's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Taysha Gene Earnings per Share Projection vs Actual
Taysha Gene Corporate Management
| Greg Gara | VP Manufacturing | Profile | |
| Tracy Porter | Chief Officer | Profile | |
| Jim Rouse | Chief Officer | Profile | |
| R II | President, Founder | Profile | |
| FFPM MSc | Chief RD | Profile | |
| Steven Gray | Chief Program | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Taysha Gene Therapies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Taysha Gene. If investors know Taysha will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Taysha Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.63 | Revenue Per Share | Quarterly Revenue Growth (0.62) | Return On Assets | Return On Equity |
The market value of Taysha Gene Therapies is measured differently than its book value, which is the value of Taysha that is recorded on the company's balance sheet. Investors also form their own opinion of Taysha Gene's value that differs from its market value or its book value, called intrinsic value, which is Taysha Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Taysha Gene's market value can be influenced by many factors that don't directly affect Taysha Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Taysha Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taysha Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Taysha Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.